Avantor, Inc. provides products and services to clients in the biopharmaceutical, healthcare, education and government, advanced technologies and applied materials industries in America, Europe, Asia, the Middle East and Africa. The company is headquartered in Radnor, Pennsylvania.
| Revenue (TTM) | $6.64B |
| Gross Profit (TTM) | $2.10B |
| EBITDA | $947.60M |
| Operating Margin | 8.19% |
| Return on Equity | 5.91% |
| Return on Assets | 2.83% |
| Revenue/Share (TTM) | $9.80 |
| Book Value | $8.61 |
| Price-to-Book | 1.76 |
| Price-to-Sales (TTM) | 1.58 |
| EV/Revenue | 2.031 |
| EV/EBITDA | 15.03 |
| Quarterly Earnings Growth (YoY) | -37.40% |
| Quarterly Revenue Growth (YoY) | 4.60% |
| Shares Outstanding | $677.62M |
| Float | $659.01M |
| % Insiders | 1.53% |
| % Institutions | 105.77% |
Volatility is currently expanding
Avantor (AVTR) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Does Avantor, Inc. (AVTR) have what it takes to be a top stock pick for momentum investors? Let's find out.
Here is how Avantor, Inc. (AVTR) and Novartis (NVS) have performed compared to their sector so far this year.
Avantor NYSE: AVTR reported a return to organic revenue growth in the third quarter of 2026, led by accelerating performance in its VWR Distribution & Services segment and a return to growth in its Bioscience & Medtech Products business.
RADNOR, Pa., Oct. 26, 2026 /PRNewswire/ -- Avantor, Inc. (NYSE: AVTR), a leading global provider of mission-critical products and services to customers in the life sciences and advanced technology industries, welcomes Mikey Santiago as its new Chief Information Officer.
The market is regaining confidence in Avantor's ability to grow organically and in Emmanuel Ligner's turnaround plan. Biopharma company Regeneron reported a solid set of results, with key drug Dupixent continuing to outpace our and the market's growth expectations. Building products company Fortune Brands Innovations saw its stock price decline in Q3, retracing Q2's positive move related to excitement over Jesse Singh's appointment as CEO.
AVTR's improving commercial execution, specialty product strength and raised 2026 outlook signal recovery potential despite lingering demand challenges.
Investors looking for stocks in the Medical Services sector might want to consider either Viatris (VTRS) or Avantor, Inc. (AVTR). But which of these two stocks is more attractive to value investors?
RADNOR, Pa., Oct. 1, 2026 /PRNewswire/ -- Avantor, Inc. (NYSE: AVTR), a leading global provider of mission-critical products and services to customers in the life sciences and advanced technology industries, will release its third quarter 2026 financial results before the market opens on Wednesday, October 28, and will hold a related conference call on the same day at 8:00 a.m.
Here is how Avantor, Inc. (AVTR) and BrightSpring Health Services, Inc. (BTSG) have performed compared to their sector so far this year.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on AVTR and any ticker you trade — then tracks every position and per-strategy win rate.
